文献速递肿瘤 PET/CT

非肿瘤PET/CT放射组学改善宫颈癌治疗失败预后预测

Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics.
PubMed 文献 · J Nucl Med · 2021-10-28

本研究纳入127例接受根治性放化疗的局部晚期宫颈癌患者,利用治疗前全身18F-FDG PET/CT提取肿瘤及全身肌肉、骨骼、脂肪的放射组学特征,构建Cox复发模型并在32例患者中验证。含非肿瘤放射组学特征的模型风险分层风险比为0.019(95%CI 0.004-0.082),优于仅基于临床分期的0.36(95%CI 0.16-0.83)。

要点

  • 纳入非肿瘤放射组学特征可提升宫颈癌复发预测模型性能。
  • 含1个临床、2个GTV、1个PTV及1个全身放射组学标志物的Cox模型表现最优。
  • 该模型风险分层风险比0.019,优于临床分期单独分层的0.36。

核心结论

  • 纳入非肿瘤放射组学生物标志物可改善预后模型性能,优于仅使用临床和肿瘤放射组学标志物。

研究设计与样本

  • 回顾性分析127例接受根治性放化疗和腔内近距离治疗的初治局部晚期宫颈癌患者,所有患者治疗前接受全身18F-FDG PET/CT。
  • 95例用于训练含放射组学和临床特征的Cox复发模型,32例用于测试模型泛化能力并计算c-index。

主要发现

  • 最优Cox模型包含1个临床生物标志物(肿瘤是否为III-IVA期)、2个GTV放射组学标志物、1个PTV放射组学标志物和1个全身放射组学标志物。
  • 基于该模型线性风险评分进行高、低风险分层,风险比为0.019(95%CI 0.004-0.082)。
  • 基于临床分期单独分层的风险比为0.36(95%CI 0.16-0.83)。

关键数值与推荐

  • 从GTV、PTV、肌肉、骨骼和脂肪中共提取965个放射组学特征。
  • 最优模型包含的GTV放射组学标志物为PET灰度尺寸区域矩阵小面积低灰度强调和区域熵。
  • 最优模型包含的PTV放射组学标志物为长轴长度,全身放射组学标志物为CT骨骼均方根。

临床怎么用

  • 对于局部晚期宫颈癌患者,治疗前全身PET/CT放射组学分析可用于辅助预测放化疗后复发风险。
  • 结合非肿瘤组织放射组学特征的风险分层可能优于仅依赖临床分期。

局限性

  • 研究为单中心回顾性分析,样本量有限(127例)。
  • 未来需在更大规模、多机构队列中进一步验证这些模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiomics has been applied to predict recurrence in several disease sites, but current approaches are typically restricted to analyzing tumor features, neglecting nontumor information in the rest of the body. The purpose of this work was to develop and validate a model incorporating nontumor radiomics, including whole-body features, to predict treatment outcomes in patients with previously untreated locoregionally advanced cervical cancer. Methods: We analyzed 127 cervical cancer patients treated definitively with chemoradiotherapy and intracavitary brachytherapy. All patients underwent pretreatment whole-body 18F-FDG PET/CT. To quantify effects due to the tumor itself, the gross tumor volume (GTV) was directly contoured on the PET/CT image. Meanwhile, to quantify effects arising from the rest of the body, the planning target volume (PTV) was deformably registered from each planning CT to the PET/CT scan, and a semiautomated approach combining seed-growing and manual contour review generated whole-body muscle, bone, and fat segmentations on each PET/CT image. A total of 965 radiomic features were extracted for GTV, PTV, muscle, bone, and fat. Ninety-five patients were used to train a Cox model of disease recurrence including both radiomic and clinical features (age, stage, tumor grade, histology, and baseline complete blood cell counts), using bagging and split-sample-validation for feature reduction and model selection. To further avoid overfitting, the resulting models were tested for generalization on the remaining 32 patients, by calculating a risk score based on Cox regression and evaluating the c-index (c-index > 0.5 indicates predictive power). Results: Optimal performance was seen in a Cox model including 1 clinical biomarker (whether or not a tumor was stage III-IVA), 2 GTV radiomic biomarkers (PET gray-level size-zone matrix small area low gray level emphasis and zone entropy), 1 PTV radiomic biomarker (major axis length), and 1 whole-body radiomic biomarker (CT bone root mean square). In particular, stratification into high- and low-risk groups, based on the linear risk score from this Cox model, resulted in a hazard ratio of 0.019 (95% CI, 0.004, 0.082), an improvement over stratification based on clinical stage alone, which had a hazard ratio of 0.36 (95% CI, 0.16, 0.83). Conclusion: Incorporating nontumor radiomic biomarkers can improve the performance of prognostic models compared with using only clinical and tumor radiomic biomarkers. Future work should look to further test these models in larger, multiinstitutional cohorts.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yusufaly TI, Zou J, Nelson TJ, et al. Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics. J Nucl Med. 2021. PMID: 34711618. doi:10.2967/jnumed.121.262618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。